Sunbelt Securities Inc. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 625 shares of the life sciences company’s stock, valued at approximately $230,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Strategy Asset Managers LLC acquired a new stake in Illumina in the 1st quarter worth about $26,000. C J Advisory Inc acquired a new stake in Illumina in the 1st quarter worth about $29,000. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Illumina in the 2nd quarter worth about $37,000. Valeo Financial Advisors LLC boosted its stake in Illumina by 130.0% in the 1st quarter. Valeo Financial Advisors LLC now owns 115 shares of the life sciences company’s stock worth $36,000 after buying an additional 65 shares during the last quarter. Finally, Mizuho Securities Co. Ltd. acquired a new stake in Illumina in the 1st quarter worth about $37,000. 90.95% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Robert P. Ragusa sold 2,230 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $293.09, for a total transaction of $653,590.70. Following the completion of the transaction, the senior vice president now owns 10,685 shares in the company, valued at approximately $3,131,666.65. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jay T. Flatley sold 3,300 shares of Illumina stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $304.44, for a total value of $1,004,652.00. Following the sale, the director now directly owns 282,516 shares in the company, valued at approximately $86,009,171.04. The disclosure for this sale can be found here. In the last quarter, insiders sold 50,458 shares of company stock valued at $16,527,618. Insiders own 0.38% of the company’s stock.

NASDAQ ILMN traded up $0.47 during mid-day trading on Thursday, reaching $285.54. 21,636 shares of the company’s stock traded hands, compared to its average volume of 1,242,876. The stock has a market capitalization of $41.98 billion, a P/E ratio of 50.03, a price-to-earnings-growth ratio of 2.71 and a beta of 1.10. The firm’s fifty day simple moving average is $321.15. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42. Illumina, Inc. has a 1-year low of $268.62 and a 1-year high of $380.76.

Illumina (NASDAQ:ILMN) last issued its earnings results on Monday, July 29th. The life sciences company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.32 by $0.03. The company had revenue of $838.00 million during the quarter, compared to analyst estimates of $835.12 million. Illumina had a return on equity of 21.73% and a net margin of 27.56%. The business’s revenue was up 1.0% on a year-over-year basis. During the same quarter last year, the firm earned $1.43 EPS. Equities analysts expect that Illumina, Inc. will post 6.04 earnings per share for the current year.

ILMN has been the topic of a number of research reports. Cowen cut their price objective on Illumina from $380.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, July 12th. Argus cut their price objective on Illumina to $340.00 and set a “buy” rating on the stock in a report on Thursday, July 18th. Canaccord Genuity downgraded Illumina from a “buy” rating to a “hold” rating and cut their price objective for the stock from $330.00 to $300.00 in a report on Tuesday, July 30th. BidaskClub downgraded Illumina from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 13th. Finally, Deutsche Bank cut their price objective on Illumina from $290.00 to $280.00 and set a “hold” rating on the stock in a report on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have issued a buy rating to the stock. Illumina presently has a consensus rating of “Buy” and an average target price of $330.92.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Featured Article: What is quantitative easing?

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.